<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0603233325
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2005
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        SERETIDE EVOHALER 25/50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUTICASONE PROPIONATE,SALMETEROL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Inhalation use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Pressurised inhalation, suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pressurised container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        79.90
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXO SAUDI ARABIA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 1182]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLAXO SAUDI ARABIA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R03AK06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Seretide Evohaler contains two medicines, salmeterol and fluticasone propionate:&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salmeterol is a (long-acting beta2 agonist) bronchodilator. Bronchodilators help the airways in the lungs to stay open. This makes it easier for air to get in and out. The effects last for at least 12 hours.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fluticasone propionate is a corticosteroid which reduces swelling and irritation in the lungs.</p><p>The doctor has prescribed this medicine to help prevent breathing problems such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Asthma.</p><p>You must use Seretide every day as directed by your doctor. This will make sure that it works properly in controlling your asthma.&nbsp;</p><p>Seretide helps to stop breathlessness and wheeziness coming on. It does not work once you are breathless or wheezy. If that happens, you need to use a fast acting &lsquo;reliever&rsquo; medication, such as salbutamol.</p><p>Ask your doctor or pharmacist if you would like any further explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Seretide Evohaler:</strong></p><p>You are allergic (hypersensitive) to salmeterol, fluticasone propionate or to the other ingredient in Seretide Evohaler.</p><p>&nbsp;</p><p>If you are not sure, talk to your doctor or pharmacist before taking Seretide Evohaler.</p><p>&nbsp;</p><p><strong>Take special care with Seretide Evohaler</strong></p><p>Check with your doctor or pharmacist before taking Seretide Evohaler if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have acute symptoms (use fast reliever bronchodilator).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have overactive thyroid gland.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are using asthma relievers so frequent.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have or previously had tuberculosis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have high blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have Heart disease, including an irregular or fast heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have kidney problems, if your doctor transferring you from oral to inhaled cortisone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have diabetes mellitus.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have low potassium in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The current dose of Seretide failed to give adequate control of asthma.</p><p>If you are stopping the treatment do not to stop abruptly due to the risk of the symptoms worsening.</p><p>If you have sudden and progressive deterioration in control of asthma (it is life threatening), you should contact your doctor and he might increase the cortisone dose.</p><p>Increasing the use of fast reliever bronchodilator is indicator for case deterioration.</p><p>Your treatment plan will be titrated to the lowest dose that gives an effective control and maintain it.</p><p>If your child is asthmatic and treated with Seretide, his height will be monitored by his doctor.</p><p>You should carry steroid warning card if you are transferring from systemic to inhaled therapy.</p><p>You should discontinue Seretide if you feel increase in wheezing after taking dose and take immediately fast and short acting bronchodilator.</p><p>If your heart rate gets faster, this will be transient effect and tend to reduce with regular therapy.</p><p>If you are not sure if any of the above applies to you, talk to your doctor, pharmacist before using Seretide Evohaler.</p><p><strong>Giving other medicines, herbal or dietary supplements </strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines for asthma or any medicines that you buy without a prescription and herbal medicines. This is because Seretide Evohaler can affect the way some medicines work. Also some other medicines can affect the way Seretide Evohaler works.</p><p>In particular, tell your doctor, pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta blockers, such as propranolol used to treat irregular or fast heart beats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antiviral and antifungal medicines (such as ritonavir, and ketoconazole).</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before using Seretide Evohaler.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>As with all medicines, do not use Seretide if you are pregnant, especially in the first 3 months, unless considered essential by your doctor.</p><p>Talk to your doctor or pharmacist before taking Seretide if you are or might be pregnant or lactating.</p><p>Ask your doctor for advice before taking any medicine.</p><p><strong>&nbsp;</strong></p><p><strong>Effects on ability to drive and use machines</strong></p><p>Seretide has no reports on affecting your ability to drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Seretide Evohaler exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. The dose has been prescribed will depend on the treatment plan.</p><p><strong>How to take Seretide Evohaler</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not increase the dose without medical advice.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seretide Evohaler is administered by the oral inhaled route only.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use Seretide Evohaler regularly for optimum benefit.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use a spacer device if you find it difficult to synchronize aerosol actuation with inspiration of breath.</p><p>Changing from corticosteroid alone to combination therapy will make you benefit either by more control of asthma or decreasing the dose of corticosteroid.</p><p><strong>&nbsp;</strong></p><p><strong>Asthma</strong></p><p><strong>Adults and adolescents 12 years and older:-</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seretide 25mcg/50 mcg Evohaler - Two inhalations twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seretide 25mcg/125mcg Evohaler - Two inhalations twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seretide 25mcg/250mcg Evohaler - Two inhalations twice a day.</p><p><strong>Children 4 years and older:-</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seretide 25mcg/50mcg Evohaler - Two inhalations twice a day.</p><p><strong>Children under 4 years:</strong></p><p>No data available for use of SERETIDE in children aged less than 4 years.</p><p>&nbsp;</p><p>Your symptoms may become well controlled using Seretide twice a day. If so, your doctor may decide to reduce your dose to once a day.</p><p>&nbsp;</p><p>It is very important to follow your doctor&rsquo;s instructions on how many inhalations to take and how often to take your medicine.</p><p>&nbsp;</p><p><strong>If your asthma or breathing gets worse tell your doctor straight away</strong>. You may find that you feel more wheezy, your chest feels tight more often or you may need to use more of your fast acting &lsquo;reliever&rsquo; medicine. If any of these happen, you should continue to take Seretide but do not increase the number of puffs you take. Your chest condition may be getting worse and you could become seriously ill. See your doctor as you may need additional treatment.</p><p><strong>&nbsp;</strong></p><p><strong>Special patient group</strong></p><p>There is no need to adjust the dose in the elderly or in those with kidney or liver problems.</p><p><strong>&nbsp;</strong></p><p><strong>If you use more Seretide Evohaler than you should</strong></p><p>If you use more Seretide Evohaler than you should, talk to a doctor or go to a hospital straight away. Take the medicine pack with you.</p><p><strong>The following effects may happen:</strong></p><p>Effects due to Salmeterol</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your heart beating may be faster than usual.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You feel shaky.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood pressure becomes high.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You may have headache, muscle weakness, and joints ache.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood potassium becomes low.</p><p>Effects due to Fluticasone</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Temporary suppression to HPA axis.</p><p>Seretide Evohaler may affect the normal production of steroid hormones in the body, particularly if you have taken high doses for long periods of time particularly in children. The effects include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your blood glucose becomes low (lead to unconsciousness and convulsions) this is triggered by stress (Trauma, Surgery, Infection or rapid reduction in dosage of corticosteroid.</p><p>&nbsp;</p><p>Your doctor will check you regularly for any of these side effects to give you the lowest dose of Seretide to control your asthma.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you have used larger doses for a long period of time, you should talk to your doctor or pharmacist for advice. This is because larger doses of Seretide may reduce the amount of steroid hormones produced by the adrenal gland.</p><p><strong>&nbsp;</strong></p><p><strong>If you forget to take Seretide Evohaler&nbsp; &nbsp;&nbsp;&nbsp;</strong></p><p>If you miss a dose:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take Seretide Evohaler as soon as possible, then</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; take your next dose at the usual time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not give a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p><strong>Stopping taking Seretide Evohaler&nbsp; &nbsp;&nbsp;</strong></p><p>Do not stop taking Seretide Evohaler without talking to your doctor. Continue until the treatment is finished, even if you feel better.</p><p>&nbsp;</p><p>If you have any further question on the use of this product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Seretide Evohaler can cause side effects, although not everybody gets them.</p><p><strong>Allergic reactions </strong></p><p>If you have an allergic reaction, stop taking Seretide and see a doctor straight away. The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheezing and chest pain or chest tightness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your eyelids, face, lips, mouth or tongue.</p><p>&nbsp;</p><p>Other side effects are listed below:</p><p><strong>Very common (affects more than 1 in 10 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache.</p><p><strong>Common (affects more than 1 in 100 people and less than 1 in 10 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infection caused by Candida in the mouth (Thrush) and throat. Muscle cramps, joints pain.</p><p><strong>Uncommon (affects more than or equal to 1 in 1000 people and less than 1 in 100 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin allergic reactions.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Collection of blood in the tissue (contusions).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased and irregular heartbeats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tremors.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, sleep disorder.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low potassium in blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Opacity in eye lens.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Horse voice, Throat irritation.</p><p><strong>Rare (affects more than or equal to 1 in 10000 people and less than 1 in 1000 people) </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including serious allergic reaction causing swelling of the face, tongue or throat which may cause difficulty in swallowing or breathing, itchy, bumpy rash (hives), chest tightness causing difficulty in breathing, Low blood pressure that can cause light-headedness on standing up and collapse.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pressure in the eye.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in mood including irritability and increased activity (mainly in children).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest tightness causing difficulty in breathing or wheezing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fast heartbeats.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling in the face and neck.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, slowing the growth in children and adolescents, bone thinning.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fungal infection caused by Candida in the oesophagus (gullet), which might cause difficulties in swallowing.</p><p>&nbsp;</p><p>If your asthma gets worse straight after taking Seretide, stop using your Seretide Evohaler. Use your fast-acting &lsquo;reliever&rsquo; inhaler to help your breathing and tell your doctor straight away.</p><p>&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep out of the reach and sight of children.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Straight after use, replace the mouthpiece cover firmly and snap it into position.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Seretide Evohaler after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Seretide Evohaler in dry place below 30&deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Protect from frost and direct heat or sunlight.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not cool the canister, since cooling decreases the therapeutic effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The container contains a pressurised liquid. Do not expose to temperatures higher than 50&deg;C. Do not puncture, break or burn the inhaler even when it is apparently empty.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor tells you to stop taking Seretide Evohaler, it is important to return any remnants which are left over to your pharmacist.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Seretide Evohaler contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Active ingredients:</p><p><strong><em>Seretide Evohaler 50 </em></strong>contains 25 micrograms salmeterol (as salmeterol xinafoate) and 50 micrograms fluticasone propionate.</p><p><strong><em>Seretide Evohaler 125</em></strong> contains 25 micrograms salmeterol (as salmeterol xinafoate) and 125 micrograms fluticasone propionate.</p><p><strong><em>Seretide Evohaler 250</em></strong> contains 25 micrograms salmeterol (as salmeterol xinafoate) and 250 micrograms fluticasone propionate.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other non active ingredients:</p><p>Non-CFC propellant (HFA 134a)</p><p>&nbsp;</p><p><strong>Instruction for using your Seretide Evohaler:</strong></p><p>Testing your Evohaler:</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>4. Hold the inhaler upright between fingers and thumb with your thumb on the base, below the mouthpiece</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>3. Shake the inhaler well to ensure that any loose objects are removed and that the contents of the inhaler are evenly mixed.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>1. Remove the mouthpiece cover by gently squeezing the sides of the cover.</p><p>2. Check inside and outside of the inhaler including the mouthpiece for the presence of loose objects.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr></tbody></table><p>Before using for the first time or if your inhaler has not been used for a week or more remove the mouthpiece cover by gently squeezing the sides of the cover, shake the inhaler well, and release two puffs into the air to make sure that it works.</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>7. While holding your breath, take the inhaler from your mouth and take your finger from the top of the inhaler.&nbsp; Continue holding your breath for as long as is comfortable.</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>6. Just after starting to breathe in through your mouth, press firmly down on the top of the inhaler to release salmeterol and fluticasone propionate, while still breathing in steadily and deeply</p><p>&nbsp;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p>5. Breathe out as far as it is comfortable and then place the mouthpiece in your mouth between your teeth and close your lips around it, but do not bite it.</p></td></tr></tbody></table><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&lrm;8. To take the second puff keep the inhaler upright and wait about half a minute &lrm;before repeating steps 3 to 7.&lrm;</p><p>&lrm;9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Afterwards rinse your mouth with water and spit it out.</p><p>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the mouthpiece cover by firmly pushing and snapping the cap into position.</p><p><strong>IMPORTANT:-</strong></p><p>Do not rush stages 5, 6 and 7.&nbsp; It is important that you start to breathe in as slowly as &lrm;possible just before operating your inhaler.&nbsp; Practise in front of a mirror for the first few &lrm;times.&nbsp; If you see &quot;mist&quot; coming from the top of your inhaler or the sides of your mouth &lrm;you should start again from stage 2.&lrm;</p><p>If your doctor has given you different instructions for using your inhaler, please follow &lrm;them carefully. Tell your doctor if you have any difficulties.&lrm;</p><p><strong>Children:-&lrm;</strong></p><p>Young children may need help and an adult may need to operate the inhaler for them. &lrm;Encourage the child to breathe out and operate the inhaler just after the child starts to &lrm;breathe in.&nbsp; Practice the technique together.&nbsp; Older children or people with weak hands &lrm;should hold the inhaler with both hands.&nbsp; Put the two forefingers on top of the inhaler and &lrm;both thumbs on the base below the mouthpiece.&lrm;</p><p><strong>Cleaning:-&lrm;</strong></p><p>Your inhaler should be cleaned at least once a week.&lrm;</p><p>&lrm;1.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the mouth piece cover.&lrm;</p><p>&lrm;2.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not remove the canister from the plastic casing.&lrm;</p><p>&lrm;3.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wipe the inside and outside of the mouthpiece and the plastic casing with a dry &lrm;cloth, tissue or cotton bud.&lrm;</p><p>&lrm;4.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the mouthpiece cover.&lrm;</p><p>DO NOT PUT THE METAL CANISTER INTO WATER.&lrm;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Seretide Evohaler looks like and contents of the pack

·       Seretide Evohaler comprises a suspension of salmeterol and fluticasone propionate in the non-CFC propellant HFA 134a.

·       The suspension is contained in an aluminium alloy can, sealed with a metering valve.

·       The canisters are fitted into plastic actuators incorporating an atomizing orifice and fitted with dustcaps.

·       Seretide Evohaler has been formulated in three strengths and one pack size, delivering 120 actuations per inhaler.



Not all packs are available in every country.

 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Seretide and Evohaler are trademarks are owned by or licensed to the GSK group of companies</p><p><em>&copy; 2021 GSK group of companies. All Rights Reserved.</em></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Manufactured by:</strong></p><p>Glaxo Wellcome Production*, Evreux, France</p><p><strong>Packed by:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA<strong> </strong></p><p><strong>Marketing Authorisation Holder</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p><p>&nbsp;</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>-GlaxoSmithKline - Head Office, Jeddah </strong></p><p>&bull; Tel: +966-12-6536666</p><p>&bull; Mobile: +966-56-904-9882</p><p>&bull; Email: gcc.medinfo@gsk.com</p><p>&bull; Website: https://gskpro.com/en-sa/</p><p>&bull; P.O. Box 55850, Jeddah 21544, Saudi Arabia.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GDS Version Number: GDS37

Date of issue: 15 December 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">سيريتايد إيڤوهيلر يحتوي على دوائين، سالميترول وفلوتيكازون <strong>بروبيونيت</strong>:</p><ul><li dir="RTL">السالميترول عبارة عن (منشط طويل المفعول للمستقبلات الأدرينية بيتا-2) موسع للشعب. موسعات الشعب تساعد المجاري التنفسية في الرئة على أن تظل مفتوحة. وهذا يمكن الهواء من الدخول والخروج بسهولة. يستمر المفعول لمدة 12 ساعة على الأقل.</li><li dir="RTL">فلوتيكازون <strong>بروبيونيت</strong> هو كورتيزون قشري كظري يقلل الانتفاخ والتهيج في الرئة.</li></ul><p dir="RTL">وصف الطبيب هذا الدواء للمساعدة على الوقاية من مشاكل التنفس كما في:</p><ul><li dir="RTL">الربو.</li></ul><p dir="RTL">يجب أن تستعمل سيريتايد كل يوم كما أرشدك الطبيب. فذلك يضمن عمله بفعالية في التحكم بالربو.</p><p dir="RTL">سيريتايد يساعد على إيقاف ضيق التنفس والأزيز. إنه لايعمل فور شعورك بضيق التنفس أو الأزيز. إذا حدث ذلك، تحتاج لاستعمال دواء مخفف للأعراض سريع المفعول، مثل سالبيوتامول.</p><p dir="RTL">اسأل طبيبك أو الصيدلي إذا أردت أي استفسارات أخرى عن هذه الاستعمالات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا </strong>تستخدم<strong> </strong><strong>سيريتايد إيڤوهيلر إذا</strong><strong>:</strong></p><p dir="RTL">كنت مصاباً بحساسية (مفرط الحساسية) للسالميترول أو فلوتيكازون <strong>بروبيونيت</strong>، أو أي من المكونات الأخرى في سيريتايد إيڤوهيلر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكداً، تحدث مع طبيبك أو الصيدلي قبل استخدام سيريتايد إيڤوهيلر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>احتياطات</strong><strong> </strong><strong>خاصة عند استعمال سيريتايد إيڤوهيلر</strong></p><p dir="RTL">راجع مع طبيبك أو الصيدلي قبل استخدام سيريتايد إيڤوهيلر إذا:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; كانت لديك أعراض حادة (استخدم مخفف للأعراض موسع للشعب سريع المفعول).<br />&bull; كان لديك فرط نشاط الغدة الدرقية.<br />&bull; كنت تستخدم مخففات الربو بصورة متكررة.<br />&bull; كان لديك حالياً أو تاريخ سابقاً إصابة بالسل.<br />&bull; كان لديك ارتفاع في ضغط الدم.<br />&bull; كنت تعاني من أمراض في القلب، بما في ذلك عدم انتظام أو سرعة ضربات القلب.<br />&bull; كان لديك مشاكل في الكلى، إذا كان طبيبك حول علاجك من كورتيزون فموي إلى كورتيزون مستنشق.<br />&bull; كان لديك مرض السكري.<br />&bull; كان لديك انخفاض في مستوى البوتاسيوم في الدم.<br />&bull; كانت الجرعة الحالية من سيريتايد فشلت في إعطاء تحكم كافي في الربو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتوقف عن العلاج لا توقفه فجأة بسبب المخاطر من تفاقم الأعراض.<br />إذا حدث لك تدهور مفاجئ ومتزايد في السيطرة على الربو (هذا يعتبر مهدد للحياة)، يجب عليك الاتصال بالطبيب ويحتمل أن يزيد جرعة الكورتيزون.<br />زيادة استخدام مخفف للأعراض موسع للشعب سريع المفعول هو مؤشر لتدهور الحالة.<br />سيتم معايرة الجرعة العلاجية الخاصة بك إلى أدنى جرعة تعطي تحكم فعال وتحافظ عليه.<br />إذا كان طفلك مصاباً بالربو ويعالج بسيريتايد، سيتم مراقبة طوله من قبل طبيبه.<br />يجب أن تحمل بطاقة تحذير الستيرويد إذا تم تحويل علاجك من كورتيزون جهازي إلى كورتيزون مستنشق.<br />يجب عليك التوقف عن استخدام سيريتايد إذا كنت تشعر بزيادة في الأزيز بعد تناول الجرعة، واستخدام موسع للشعب سريع المفعول على الفور.<br />إذا تسارع معدل ضربات القلب، إن هذا تأثيراً عابراً ويميل إلى الإنخفاض مع استمرار العلاج.<br />&nbsp;</p><p dir="RTL">إذا لم تكن متأكداً إذا كان أى مما أعلاه ينطبق عليك، فتحدث مع طبيبك أو الصيدلي قبل استخدام سيريتايد إيڤوهيلر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول</strong><strong> </strong><strong>أدوية</strong><strong> </strong><strong>أخرى</strong><strong> </strong><strong>مع</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>الدواء،</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مستحضرات</strong><strong> </strong><strong>عشبية</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>مدعمات</strong><strong> </strong><strong>غذائية</strong></p><p dir="RTL">فضلاً أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت أدوية أخرى منذ فترة قصيرة. ويشمل هذا الأدوية التي تشتريها بدون وصفة طبية والأدوية العشبية. يرجع هذا لأن سيريتايد إيڤوهيلر، قد يؤثر على طريقة عمل بعض الأدوية. وأيضاً بعض الأدوية الأخرى يمكن أن تؤثر في طريقة عمل سيريتايد إيڤوهيلر.</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية الآتية:</p><p dir="RTL">&bull; حاصرات بيتا، مثل پروپرانولول يستخدم لعلاج عدم انتظام أو سرعة ضربات القلب.<br />&bull; الأدوية المضادة للفيروسات ومضاد للفطريات (مثل ريتوناڤير، والكيتوكونازول).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكداً إذا كان أى مما أعلاه ينطبق عليك، فتحدث مع طبيبك أو الصيدلي قبل استخدام سيريتايد إيڤوهيلر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">كشأن جميع الأدوية، لاتستخدمي سيريتايد إذا كُنتِ حامل، خاصة في الثلاثة شهور الأولى، إلا إذا اعْتُبِر هذا ضرورياً من قبل الطبيب.</p><p dir="RTL">تحدثي مع طبيبك أوالصيدلي قبل استخدام سيريتايد إذا كنت حاملا أو تخططين للحمل أو كنت تقومين بالرضاعة الطبيعية.</p><p dir="RTL">يجب استشارة الطبيب قبل استخدام أي دواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التأثيرات</strong><strong> </strong><strong>على</strong><strong> </strong><strong>القدرة</strong><strong> </strong><strong>على</strong><strong> </strong><strong>القيادة</strong><strong> </strong><strong>واستخدام</strong><strong> </strong><strong>الآلات</strong></p><p dir="RTL">لم يرد ذكر أية تقارير عن تأثير سيريتايد إيڤوهيلر على القدرة على قيادة السيارات أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تأكد دوماً من استخدام سيريتايد إيڤوهيلر تماماً كما وصف لك الطبيب. راجع طبيبك أو الصيدلي إذا كنت غير متأكد. الجرعة التي تم وصفها لك تعتمد علي الخطة العلاجية لحالتك.</p><p dir="RTL"><strong>كيف تستخدم سيريتايد إيڤوهيلر</strong></p><ul><li dir="RTL">لا تزيد الجرعة دون استشارة طبية.</li><li dir="RTL">استخدام سيريتايد إيڤوهيلر عن طريق الإستنشاق عن طريق الفم فقط.</li><li dir="RTL">استخدم سيريتايد إيڤوهيلر بانتظام للحصول على الفوائد المثلى.</li><li dir="RTL">استخدم جهاز مباعد أذا وجدت صعوبة في تحقيق التزامن بين البخة والإستنشاق.</li></ul><p dir="RTL"><br />التغيير من الكورتيكوستيرويد وحده إلى العلاج المجمع سوف يفيدك إما عن طريق زيادة السيطرة على الربو أو خفض جرعة الكورتيكوستيرويد.<br /><br /><strong>الربو<br />البالغين والمراهقين 12 سنة فما فوق:</strong><br />سيريتايد 25 ميكروجرام/50 ميكروجرام - بختين مرتين في اليوم.<br />سيريتايد 25 ميكروجرام/125 ميكروجرام - بختين مرتين في اليوم.<br />سيريتايد 25 ميكروجرام/250 ميكروجرام - بختين مرتين في اليوم.<br /><strong>أطفال في سن 4 سنوات فما فوق:</strong><br />سيريتايد 25 ميكروجرام/50 ميكروجرام - بختين مرتين في اليوم.<br /><strong>الأطفال دون سن 4 سنوات:</strong><br />لا توجد بيانات متاحة لاستخدام سيريتايد في الأطفال الذين تقل أعمارهم عن 4 سنوات.<br /><br />قد تكون السيطرة على الأعراض بشكل جيد باستخدام سيريتايد مرتين في اليوم. إذا كان الأمر كذلك، قد يقرر طبيبك خفض الجرعة إلى مرة واحدة في اليوم.<br /><br />من المهم جداً إتباع تعليمات الطبيب حول عدد النشقات وكيفية استخدام الدواء.<br /><br /><strong>إذا ساءت حالة الربو أو التنفس أخبر طبيبك على الفور.</strong> قد تشعر بأزيز بصورة أكبر، أو تشعر بضيق في الصدر في كثير من الأحيان أو قد تحتاج لاستخدام دوائك المخفف للأعراض سريع المفعول بصورة أكبر. إذا حدث هذا، يجب أن تستمر في استخدام سيريتايد بدون زيادة عدد النشقات التي تأخذها. فقد تزداد حالة صدرك سوءاً ويمكن أن تصبح الحالة المرضية خطيرة. راجع طبيبك لأنك قد تحتاج إلى علاج إضافي.<br /><br /><strong>مجموعة خاصة من المرضى</strong><br />ليست هناك حاجة لتعديل الجرعة لدى كبار السن أو الذين يعانون من مشاكل في الكلى أو الكبد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا استخدمت سيريتايد إيڤوهيلر أكثر مما يجب</strong></p><p dir="RTL">إذا استخدمت سيريتايد إيڤوهيلر أكثر مما يجب، تحدث مع طبيب أو اذهب للمستشفى على الفور. قم بأخذ عبوة الدواء معك.</p><p dir="RTL"><strong>قد تحدث الآثار التالية:</strong><br />الآثار الناجمة عن سالميترول<br />- قد تتسارع ضربات قلبك أكثر من المعتاد.<br />- تشعر برجفة.<br />- يصبح ضغط الدم المرتفع.<br />- قد تشعر بصداع، وضعف العضلات، وآلام المفاصل.<br />- مستوى البوتاسيوم في الدم يصبح منخفض.<br />الآثار الناجمة عن فلوتيكازون<br />- تثبيط مؤقت للمحور الوِطائِيّ النخامي الكظري.<br />سيريتايد إيڤوهيلر قد يؤثر على الإنتاج الطبيعي لهرمونات الستيرويد في الجسم، خاصة إذا كنت قد استخدمت جرعات عالية لفترات طويلة من الزمن وخاصة في الأطفال. الآثار تتضمن ما يلي:<br />- مستوى السكر في الدم يصبح منخفض (يؤدي إلى فقدان الوعي والتشنجات) وهي مستحثة بالإجهاد (الصدمة، الجراحة، عدوى أو انخفاض سريع في جرعة الكورتيكوستيرويد).<br /><br />سوف يتحقق طبيبك بانتظام عن أي من هذه الآثار الجانبية ليعطيك أقل جرعة من سيريتايد للسيطرة على الربو لديك.<br /><br />إذا كنت قد استخدمت جرعات أكبر لفترة طويلة من الزمن، يجب عليك التحدث مع طبيبك أو الصيدلي للحصول على المشورة. وذلك لأن الجرعات الأكبر من سيريتايد قد تقلل من كمية هرمونات الستيرويد التي تنتجها الغدة الكظرية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت استخدام سيريتايد إيڤوهيلر</strong></p><p dir="RTL">إذا نسيت جرعة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام سيريتايد إيڤوهيلر في أسرع وقت ممكن، ثم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب استخدام الجرعة التالية في موعدها المعتاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يجوز استخدام جرعة مضاعفة للتعويض عن جرعة منسية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التوقف عن استخدام سيريتايد إيڤوهيلر</strong></p><p dir="RTL">لا تتوقف عن استخدام سيريتايد إيڤوهيلر دون التحدث مع طبيبك. استمر حتى الانتهاء من العلاج، حتى إذا كنت تشعر بتحسن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة أخرى عن استعمال هذا المستحضر، اسأل الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كشأن كافة الأدوية، قد يتسبب سيريتايد إيڤوهيلر في بعض الأعراض الجانبية، إلا أنها لا تصيب جميع الأشخاص.</p><p dir="RTL"><strong>ردود</strong><strong> </strong><strong>فعل</strong><strong> </strong><strong>تحسسية</strong><strong>:</strong></p><p dir="RTL">إذا حدثت لك حساسية، أوقف العلاج وقم بمراجعة الطبيب على الفور. قد تشتمل أعراض الحساسية على:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز مفاجئ وألم في الصدر أو ضيق في الصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجفون أو الوجه أو الشفاه أو الفم أو اللسان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية الأخرى تشتمل على ما يلي:</p><p dir="RTL"><strong>شائعة</strong><strong> </strong><strong>جداً</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثرمن 1</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>10</strong><strong> </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL"><strong>شائعة</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>1</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>100</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>وأقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>1</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>10</strong><strong> </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية تسببها المبيضات في الفم (القلاع) والحلق. تقلصات العضلات، وآلام المفاصل.</p><p dir="RTL"><strong>غير</strong><strong> </strong><strong>شائعة</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>أو</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>1000</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>وأقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>واحد</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>100</strong><strong> </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل حساسية الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في سكر الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تجمع الدم في الأنسجة (كدمات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة وعدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رجفان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلق، واضطراب النوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستوى البوتاسيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعتيم في عدسة العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صوت أجش وتهيج الحلق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong><strong> (</strong><strong>تؤثر</strong><strong> </strong><strong>على</strong><strong> </strong><strong>أكثر</strong><strong> </strong><strong>من</strong><strong> </strong><strong>1</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>10000</strong><strong> </strong><strong>شخص</strong><strong> </strong><strong>وأقل</strong><strong> </strong><strong>من</strong><strong> </strong><strong>1</strong><strong> </strong><strong>من</strong><strong> </strong><strong>بين</strong><strong> </strong><strong>1000</strong><strong> </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية بما في ذلك ردود فعل تحسسية خطيرة مما يؤدي إلى التورم في الوجه أو اللسان أو الحلق مما قد يسبب صعوبة في البلع أو التنفس، حكة، طفح (شرى)، ضيق الصدر مما يسبب صعوبة في التنفس، وانخفاض ضغط الدم الذي يمكن أن يسبب شعور بخفة في الرأس عند الوقوف قائماً وقد يتسبب في السقوط (الانهيار).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط في العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في المزاج بما في ذلك التهيج وزيادة النشاط (غالباً في الأطفال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر مما يسبب صعوبة في التنفس أو الأزيز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسارع في ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والرقبة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة كوشينج، وظواهر كوشينجية، وتثبيط الغدة الكظرية، وتباطؤ النمو في الأطفال والمراهقين، ترقق العظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى فطرية تسببها المبيضات في المريء، يمكن أن تسبب صعوبة في البلع.<br />&nbsp;</p><p dir="RTL">إذا ساءت حالة الربو لديك مباشرة بعد استخدام سيريتايد، توقف عن استخدام سيريتايد إيڤوهيلر. استخدام مخفف الأعراض سريع المفعول المستنشق للمساعدة على تنفسك وإخبر الطبيب على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا ازدادت حدة أي من الأعراض الجانبية، أو لاحظت وجود أي عرض جانبي آخر غير مذكور في هذه النشرة، فضلاً تحدث مع طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>يحفظ بعيداً عن متناول ونظر الأطفال.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع غطاء قطعة الفم بإحكام وثبته في مكانه مباشرة بعد الاستخدام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم سيريتايد إيڤوهيلر بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد كلمة &quot;Exp&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظ سيريتايد إيڤوهيلر في مكان جاف في درجة حرارة أقل من 30<sup>&deg;</sup> م.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حمايته من الصقيع ، الحرارة وضوء الشمس المباشر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تبرد البخاخ، حيث أن التبريد يقلل الفعالية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحتوى الاسطوانة المعدنية على سائل مضغوط. لا تعرضها لدرجات حرارة أعلى من 50˚ مئوية. لا تثقب، أو تكسر، أو تحرق جهاز الاستنشاق حتى وإن كانت تبدو فارغة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك الطبيب بوقف استخدام سيريتايد إيڤوهيلر، فمن المهم أن تعيد ما تبقى إلى الصيدلي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلص من الادوية عن طريق مياة الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. سوف تساعد هذه التدابير في حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>على ماذا يحتوي سيريتايد إيڤوهيلر</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة:</p><p dir="RTL"><strong><em>سيريتايد إيڤوهيلر 50</em></strong> يحتوي على 25 ميكروجرام سالميترول (على هيئة زينافويت) و50 ميكروجرام فلوتيكازون <strong>بروبيونيت</strong>.</p><p dir="RTL"><strong><em>سيريتايد إيڤوهيلر 125</em></strong> يحتوي على 25 ميكروجرام سالميترول (على هيئة زينافويت) و125 ميكروجرام فلوتيكازون <strong>بروبيونيت</strong>.</p><p dir="RTL"><strong><em>سيريتايد إيڤوهيلر 250</em></strong><em> </em>يحتوي على 25 ميكروجرام سالميترول (على هيئة زينافويت) و250 ميكروجرام فلوتيكازون <strong>بروبيونيت</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مواد أخرى غير فعالة:</p><p dir="RTL">مادة دافعة ليست كلوروفلوروكاربونية (هيدروفلوروألكان 134A).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تعليمات</strong><strong> </strong><strong>خاصة</strong><strong> </strong><strong>بالاستعمال</strong><strong>/</strong><strong>التداول</strong></p><p dir="RTL">اختبار جهاز الاستنشاق:</p><p dir="RTL">قبل الاستعمال للمرة الأولى أو إذا لم تستعمل جهاز الاستنشاق الخاص بك لمدة أسبوع أو أكثر، انزع غطاء قطعة الفم عن طريق الضغط برفق على جانبي الغطاء، ورج جهاز الاستنشاق جيداً، وأطلق نفثتين في الهواء للتأكد من أن جهاز الاستنشاق يعمل بشكل سليم.</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انزع غطاء قطعة الفم عن طريق الضغط برفق على جانبي الغطاء.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افحص جهاز الاستنشاق من الداخل والخارج شاملاً قطعة الفم للتأكد من عدم وجود أي مواد عالقة.</p></td><td style="vertical-align:top"><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رج جهاز الاستنشاق جيداً للتأكد من إزالة أي مواد عالقة وأن محتويات جهاز الاستنشاق تم مزجها على نحو متوازن.</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمسك جهاز الاستنشاق بوضع قائم بين الأصابع والإبهام، مع وضع إبهامك على القاعدة، تحت قطعة الفم.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><table dir="rtl" border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p dir="RTL"><strong>&nbsp;&nbsp; </strong></p><p dir="RTL"><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp; أطلق الزفير بقدر المستطاع<br />دون مضايقة ثم ضع قطعة الفم في فمك بين أسنانك وأغلق شفتيك حولها، لكن لا تقضمها.</p></td><td style="vertical-align:top"><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp; بمجرد البدء بالاستنشاق من خلال فمك، اضغط بإحكام للأسفل&nbsp; على قمة جهاز الاستنشاق لإطلاق السالميترول وپروپـيونات الفلوتيكازون، وأنت لا تزال تستنشق باطّراد وبعمق.</p></td><td style="vertical-align:top"><p dir="RTL">7.&nbsp;&nbsp;&nbsp;&nbsp; أخرج جهاز الاستنشاق من فمك وأنت تحتبس أنفاسك، وارفع إصبعك عن قمة جهاز الاستنشاق. استمر&nbsp;&nbsp; بحبس أنفاسك طالما ذلك لا يسبب أي مضايقة.</p><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">8.&nbsp;&nbsp;&nbsp;&nbsp; لأخذ النفثة الثانية، احتفظ بجهاز الاستنشاق في وضع قائم وانتظر لمدة نصف دقيقة تقريباً قبل أن تكرر الخطوات من 3 إلى 7.</p><p dir="RTL">9.&nbsp;&nbsp;&nbsp;&nbsp; بعد ذلك، يتم مضمضة الفم بالماء ويبصق للخارج.</p><p dir="RTL">10.&nbsp; أعد غطاء قطعة الفم إلى مكانه بالضغط على الغطاء وتثبيته في مكانه بإحكام.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>هام:</strong></p><p dir="RTL">لا تتعجل أثناء القيام بالمراحل 5، و6، و7. من المهم أن تبدأ بالاستنشاق ببطء قدر الإمكان قبل استعمال جهاز الاستنشاق مباشرةً. تمرن على ذلك أمام مرآة بضع مرات في بداية الأمر. إذا رأيت &quot;رذاذاً خفيفاً&quot; يخرج من قمة جهاز الاستنشاق أو من جانبي فمك، فعليك أن تبدأ مرة أخرى من المرحلة 2.</p><p dir="RTL">إذا أعطاك الطبيب تعليمات مختلفة لاستعمال جهاز الاستنشاق لديك، رجاءً اتبعها بدقة. أبلغ الطبيب إذا واجهتك أية صعوبات.</p><p dir="RTL"><strong>الأطفال:</strong><br />قد يحتاج الأطفال صغار السن إلى مساعدة وقد يتطلب الأمر فرد بالغ ليساعدهم على استعمال جهاز الاستنشاق. يجب تشجيع الطفل على إطلاق الزفير ثم ابدأ عمل جهاز الاستنشاق بمجرد بدء الطفل بالاستنشاق. تمرنا على تقنية الاستعمال معاً. يجب على الأطفال الأكبر سناً أو الأفراد ذوي الأيدي الضعيفة مسك جهاز الاستنشاق بكلتا اليدين. ضع السبابتين على قمة جهاز الاستنشاق وكلا الإبهامين على القاعدة تحت قطعة الفم.</p><p dir="RTL"><strong>التنظيف</strong><strong>:</strong></p><p dir="RTL">يجب تنظيف جهاز الاستنشاق الخاص بك مرة واحدة أسبوعياً على الأقل.</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp; انزع غطاء قطعة الفم.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp; لا تخرج العلبة المعدنية من الغلاف الخارجي البلاستيكي.</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp; امسح قطعة الفم من الداخل والخارج، والغلاف الخارجي البلاستيكي بقطعة قماش جافة أو منديل ورقي أو عود لتنظيف الأذن ذي رأس قطنية.</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp; أعد غطاء قطعة الفم إلى مكانه.</p><p dir="RTL">&nbsp;</p><p>لا تضع العلبة المعدنية في الماء<em>.</em></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو</strong> <strong>سيريتايد إيڤوهيلر وما هي محتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي سيريتايد إيڤوهيلر على معلق مكون من سالميترول وفلوتيكازون <strong>بروبيونيت</strong> في مادة دافعة ليست كلوروفلوروكاربونية (هيدروفلوروألكان 134A).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المعلق معبأ داخل علبة معدنية مصنوعة من سبيكة الألومنيوم، ومغلقة بإحكام بصمام لقياس الجرعة. العلب المعدنية مثبتة داخل بخاخات بلاستيكية مدمج بها فوهة لإطلاق الرذاذ، ومغلقة بغطاء محكم لمنع دخول الأتربة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تركيبة سيريتايد إيڤوهيلر متوفرة في 3 تركيزات في حجم واحد للعبوة، وكل جهاز استنشاق يعطي 120 بخة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتوفر جميع أشكال العبوات في كل بلد.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong>سيريتايد<strong> </strong>وإيڤوهيلر علامتان تجاريتان مملوكتان أو مرخصتان لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2021 جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تصنيع:</strong></p><p dir="RTL">جلاكسو ويلكم پرودكشن*، إيفرو، فرنسا</p><p dir="RTL"><strong>تعبئة:</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL"><strong>الشركة المالكة لرخصة التسويق</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، المملكة العربية السعودية</p><p dir="RTL">* شركة تنتمي إلى مجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإستفسار</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>أي</strong><strong> </strong><strong>معلومات</strong><strong> </strong><strong>عن</strong><strong> </strong><strong>هذا</strong><strong> </strong><strong>المستحضر</strong><strong> </strong><strong>الدوائي،</strong><strong> </strong><strong>يرجى</strong><strong> </strong><strong>الإتصال</strong><strong> </strong><strong>بالأرقام</strong><strong> </strong><strong>التالية</strong><strong>:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p dir="RTL">هاتف: 6536666 -12-966 +</p><p dir="RTL">المحمول:&nbsp; 9882-904-56 966 +</p><p dir="RTL">البريد اللكتروني : gcc.medinfo@gsk.com</p><p dir="RTL">الموقع الإلكتروني : https://gskpro.com/en-sa/</p><p dir="RTL">ص.ب 55850، جدة 21544، المملكة العربية السعودية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            نص رقم: GDS37

تاريخ الإصدار: 15 ديسمبر 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Seretide Evohaler 25 microgram/50 microgram per metered dose pressurised inhalation, suspension.
Seretide Evohaler 25 microgram/125 microgram per metered dose pressurised inhalation, suspension.
Seretide Evohaler 25 microgram/250 microgram per metered dose pressurised inhalation, suspension.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each single actuation of SERETIDE provides:
Salmeterol xinafoate equivalent to 25 micrograms of salmeterol and 50, 125 or 250 micrograms of fluticasone propionate.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pressurised inhalation, suspension.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ASTHMA (Reversible Obstructive Airways Disease)</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-family:"Arial",sans-serif;
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e78a8fe5-501e-4fae-b633-f46e42e9c766 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-family:"Arial",sans-serif;
mso-bidi-font-family:"Times New Roman";mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p><em>Seretide</em> is indicated in the regular treatment of asthma (Reversible Obstructive Airways Disease)</p><p>This may include:</p><p>Patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids.</p><p>Patients who are symptomatic on current inhaled corticosteroid therapy.</p><p>Patients on regular bronchodilator therapy who require inhaled corticosteroids.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Seretide</em> Evohaler is for inhalation only. A spacer device may be used in patients who find it difficult to synchronize aerosol actuation with inspiration of breath.</p><p>Patients should be made aware that <em>Seretide</em> Evohaler must be used regularly for optimum benefit, even when asymptomatic.</p><p>Patients should be regularly reassessed by a doctor, so that the strength of <em>Seretide</em> they are receiving remains optimal and is only changed on medical advice.</p><p><strong>ASTHMA (Reversible Obstructive Airways Disease)</strong></p><p>The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Where the control of symptoms is maintained with twice daily <em>Seretide</em>, titration to the lowest effective dose could include <em>Seretide</em> given once daily.</p><p>Patients should be given the strength of <em>Seretide</em> containing the appropriate fluticasone propionate dosage for the severity of their disease.</p><p>If a patient is inadequately controlled on inhaled corticosteroid therapy alone, substitution with SERETIDE at a therapeutically equivalent corticosteroid dose may result in an improvement in asthma control. For patients whose asthma control is acceptable on inhaled corticosteroid therapy alone, substitution with SERETIDE may permit a reduction in corticosteroid dose while maintaining asthma control. For further information, please refer to the &lsquo;Pharmacodynamics&rsquo; section.</p><p><strong>Recommended Doses:</strong></p><p><strong><em>Adults and adolescents 12 years and older:-</em></strong><!--[if supportFields]><b><i><span
lang=EN-US style='color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_567a837d-7971-4578-aa3b-0182b96eb9dc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></i></b><![endif]--><strong><em>&nbsp;</em></strong><!--[if supportFields]><b><i><span
lang=EN-US style='color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></i></b><![endif]--></p><p>Two inhalations of 25 micrograms salmeterol and 50 micrograms fluticasone propionate twice daily.</p><p>or</p><p>Two inhalations of 25 micrograms salmeterol and 125 micrograms fluticasone propionate twice daily.</p><p>or</p><p>Two inhalations of 25 micrograms salmeterol and 250 micrograms fluticasone propionate twice daily.</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Children 4 years and older:-</em></strong></p><p>Two inhalations of 25 micrograms salmeterol and 50 micrograms fluticasone propionate twice daily.</p><p>There are no data available for use of <em>Seretide</em> in children aged under 4 years.</p><p>&nbsp;</p><p><strong>Special patient groups:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_85c47fec-6551-4493-b891-dfca53010aa8 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>There is no need to adjust the dose in elderly patients or in those with renal or hepatic impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                SERETIDE is contraindicated in patients with a history of hypersensitivity to any of the ingredients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Seretide</em> Evohaler is not for relief of acute symptoms for which a fast and short-acting bronchodilator (e.g. salbutamol) is required.&nbsp; Patients should be advised to have their relief medication available at all times.</p><p>Increasing use of short-acting bronchodilators to relieve symptoms indicates deterioration of control and patients should be reviewed by a physician.</p><p>Sudden and progressive deterioration in control of asthma is potentially life-threatening and the patient should be reviewed by a physician.&nbsp; Consideration should be given to increasing corticosteroid therapy.&nbsp; Also, where the current dosage of <em>Seretide</em> has failed to give adequate control of asthma, the patient should be reviewed by a physician.</p><p><s>&nbsp;</s></p><p>Treatment with <em>Seretide</em> should not be stopped abruptly in patients with asthma due to risk of exacerbation, therapy should be titrated-down under physician supervision.</p><p>&nbsp;</p><p><em>Seretide</em> should be administered with caution in patients with thyrotoxicosis.</p><p>Cardiovascular effects, such as increases in systolic blood pressure and heart rate, may occasionally be seen with all sympathomimetic drugs, especially at higher than therapeutic doses. For this reason, SERETIDE should be used with caution in patients with pre-existing cardiovascular disease.</p><p>A transient decrease in serum potassium may occur with all sympathomimetic drugs at higher therapeutic doses. Therefore, SERETIDE should be used with caution in patients predisposed to low levels of serum potassium.</p><p>Systemic effects may occur with any inhaled corticosteroid, particularly at high doses prescribed for long periods; these effects are much less likely to occur than with oral corticosteroids (<em>see Overdose</em>).&nbsp; Possible systemic effects include Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decrease in bone mineral density, cataract, glaucoma and central serous chorioretinopathy. &nbsp;</p><p>It is important, therefore for asthma patients, that the dose of inhaled corticosteroid is titrated to the lowest dose at which effective control is maintained.</p><p>The possibility of impaired adrenal response should always be borne in mind in emergency and elective situations likely to produce stress and appropriate corticosteroid treatment considered (<em>see Overdose</em>).</p><p>It is recommended that the height of children receiving prolonged treatment with inhaled corticosteroid is regularly monitored.</p><p><s>&nbsp;</s></p><p>Because of the possibility of impaired adrenal response, patients transferring from oral steroid therapy to inhaled fluticasone propionate therapy should be treated with special care, and adrenocortical function regularly monitored.</p><p>Following introduction of inhaled fluticasone propionate, withdrawal of systemic therapy should be gradual and patients encouraged to carry a steroid warning card indicating the possible need for additional therapy in times of stress.</p><p>There have been very rare reports of increases in blood glucose levels (see Adverse Reactions) and this should be considered when prescribing to patients with a history of diabetes mellitus.</p><p>During post-marketing use, there have been reports of clinically significant drug interactions in patients receiving fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing&rsquo;s syndrome and adrenal suppression.&nbsp; Therefore, concomitant use of fluticasone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects (<em>see Interactions)</em>.</p><p>&nbsp;</p><p>It was observed in a drug interaction study that concomitant use of systemic ketoconazole increases exposure to <em>SEREVENT</em>. This may lead to prolongation in the QTc interval. Caution should be exercised when strong CYP3A4 inhibitors (e.g. ketoconazole) are co-administered with <em>SEREVENT</em>. (<em>see Interactions, and Pharmacokinetics</em>).7</p><p>&nbsp;</p><p>As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing after dosing.&nbsp; This should be treated immediately with a fast and short-acting inhaled bronchodilator.&nbsp; Salmeterol-FP Accuhaler/Diskus or Evohaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary<em>.(see Adverse Reactions)</em></p><p>The pharmacological side-effects of beta-2 agonist treatment, such as tremor, subjective palpitations and headache have been reported, but tend to be transient and to reduce with regular therapy. <em>(see Adverse Reactions)</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Both non-selective and selective beta-blockers should be avoided unless there are compelling reasons for their use.</p><p>Under normal circumstances, low plasma concentrations of fluticasone propionate are achieved after inhaled dosing, due to extensive first pass metabolism and high systemic clearance mediated by cytochrome P450 3A4 in the gut and liver.&nbsp; Hence, clinically significant drug interactions mediated by fluticasone propionate are unlikely.</p><p>A drug interaction study in healthy subjects has shown that ritonavir (a highly potent cytochrome P450 3A4 inhibitor) can greatly increase fluticasone propionate plasma concentrations, resulting in markedly reduced serum cortisol concentrations.&nbsp; During post-marketing use, there have been reports of clinically significant drug interactions in patients receiving intranasal or inhaled fluticasone propionate and ritonavir, resulting in systemic corticosteroid effects including Cushing&rsquo;s syndrome and adrenal suppression.&nbsp; Therefore, concomitant use of fluticasone propionate and ritonavir should be avoided, unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side-effects.</p><p>Studies have shown that other inhibitors of cytochrome P450 3A4 produce negligible (erythromycin) and minor (ketoconazole) increases in systemic exposure to fluticasone propionate without notable reductions in serum cortisol concentrations.&nbsp; Nevertheless, care is advised when co-administering potent cytochrome P450 3A4 inhibitors (e.g. ketoconazole) as there is potential for increased systemic exposure to fluticasone propionate.</p><p>Co-administration of ketoconazole and <em>SEREVENT</em> resulted in a significant increase in plasma salmeterol exposure (1.4-fold Cmax and 15-fold AUC) and this may cause a prolongation of the QTc interval. (<em>see Warnings and Precautions, and Pharmacokinetics</em>)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no data on human fertility.&nbsp; Animal studies indicate no effects of fluticasone propionate or salmeterol xinafoate on male or female fertility.</p><p><em>Pregnancy Category C:</em> There are limited data in pregnant women.&nbsp; Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus or child.</p><p>Results from a retrospective epidemiological study did not find an increased risk of major congenital malformations (MCMs) following exposure to fluticasone propionate when compared to other inhaled corticosteroids, during the first trimester of pregnancy (<em>see Pharmacodynamics</em>).</p><p>Reproductive toxicity studies in animals, either with single drug or in combination, revealed the foetal effects expected at excessive systemic exposure levels of a potent beta<sub>2</sub>-adrenoreceptor agonist and glucocorticosteroid.&nbsp; Extensive clinical experience with drugs in these classes has revealed no evidence that the effects are relevant at therapeutic doses.&nbsp;</p><p>Salmeterol and fluticasone propionate concentrations in plasma after inhaled therapeutic doses are very low and therefore concentrations in human breast milk are likely to be correspondingly low.&nbsp; This is supported by studies in lactating animals, in which low drug concentrations were measured in milk.&nbsp; There are no data available for human breast milk.</p><p>Administration during lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the child.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no specific studies of the effect of <em>Seretide</em> on the above activities, but the pharmacology of both drugs does not indicate any effect.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All of the adverse reactions associated with the individual components, salmeterol xinafoate and fluticasone propionate, are listed below.&nbsp; There are no additional adverse reactions attributed to the combination product when compared to the adverse event profiles of the individual components.</p><p>Adverse events are listed below by system organ class and frequency.&nbsp; Frequencies are defined as: very common (&ge; 1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1000) and very rare (&lt;1/10,000).&nbsp; The majority of frequencies were determined from pooled clinical trial data from 23 asthma studies.&nbsp; Not all events were reported in clinical trials.&nbsp; For these events, the frequency was calculated based on spontaneous data.</p><p>&nbsp;</p><p>4.8.1&nbsp;&nbsp;&nbsp;&nbsp; Clinical Studies Experience<!--[if supportFields]><span lang=EN-US style='font-size:12.0pt;
color:black;mso-ansi-language:EN-US'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_02806eb5-33a7-4498-bfa7-cdda3188ea54 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-US style='font-size:12.0pt;color:black;mso-ansi-language:EN-US'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><em>&nbsp;</em></p><p><em>Infections and infestations</em></p><p>Common:&nbsp; Candidiasis of mouth and throat.</p><p>Rare: Oesophageal candidiasis.</p><p><em>Immune system disorders</em></p><p>Hypersensitivity Reactions:</p><p>Uncommon:&nbsp; Cutaneous hypersensitivity reactions, dyspnoea.</p><p>Rare:&nbsp; Anaphylactic reactions</p><p><em>Endocrine disorders</em></p><p>Possible systemic effects include (see Warnings and Precautions):</p><p>Uncommon:&nbsp; Cataract</p><p>Rare:&nbsp; Glaucoma</p><p><em>Metabolism and nutrition disorders</em></p><p>Uncommon:&nbsp; Hyperglycaemia.</p><p><em>Psychiatric disorders</em></p><p>Uncommon:&nbsp; Anxiety, sleep disorders.</p><p>Rare:&nbsp; Behavioural changes, including hyperactivity and irritability (predominantly in children).</p><p><em>Nervous system disorders</em></p><p>Very common:&nbsp; Headache. (see Warnings and Precautions)</p><p>Uncommon:&nbsp; Tremor. (see Warnings and Precautions)</p><p><em>Cardiac disorders</em></p><p>Uncommon:&nbsp; Palpitations (see Warnings and Precautions), tachycardia, atrial fibrillation.</p><p>Rare: Cardiac arrhythmias including supraventricular tachycardia and extrasystoles.</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Common:&nbsp; Hoarseness/dysphonia.</p><p>Uncommon:&nbsp; Throat irritation.</p><p><em>Skin and subcutaneous tissue disorders</em></p><p>Uncommon: Contusions.</p><p><em>Musculoskeletal and connective tissue disorders</em></p><p>Common:&nbsp; Muscle cramps, arthralgia.</p><p>4.8.2&nbsp;&nbsp;&nbsp;&nbsp; Post-marketing Experience</p><p><em>Immune system disorders</em></p><p>Hypersensitivity reactions manifesting as:</p><p>Rare:&nbsp; Angioedema (mainly facial and oropharyngeal oedema) and bronchospasm.</p><p><em>Endocrine disorders</em></p><p>Possible systemic effects include (see Warnings and Precautions):</p><p>Rare:&nbsp; Cushing&rsquo;s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density.</p><p><em>Respiratory, thoracic and mediastinal disorders</em></p><p>Rare:&nbsp; Paradoxical bronchospasm (see Warnings and Precautions)</p><p><strong>&nbsp;</strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>SFDA Call Centre: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: saudi.safety@gsk.com &nbsp;&nbsp;&nbsp;</li><li>Website: https://gskpro.com/en-sa/ &nbsp;</li></ul><ul><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The available information on overdose with <em>Seretide</em>, salmeterol and/or fluticasone propionate is given below:</p><p>The expected symptoms and signs of salmeterol overdosage are those typical of excessive beta2&ndash;adrenergic stimulation, including tremor, headache, tachycardia, increases in systolic blood pressure and hypokalaemia. There is no specific treatment for an overdose of salmeterol and fluticasone propionate. If overdose occurs, the patients should be teated supportively with appropriate monitoring as necessary<strong><em>.</em></strong></p><p>Acute inhalation of fluticasone propionate doses in excess of those approved may lead to temporary suppression of the hypothalamic-pituitary-adrenal axis.&nbsp; This does not usually require emergency action as normal adrenal function typically recovers within a few days.</p><p>If higher than approved doses of <em>Seretide</em> are continued over prolonged periods, significant adrenocortical suppression is possible.&nbsp; There have been very rare reports of acute adrenal crisis, mainly occurring in children exposed to higher than approved doses over prolonged periods (several months or years); observed features have included hypoglycaemia associated with decreased consciousness and/or convulsions.&nbsp; Situations which could potentially trigger acute adrenal crisis include exposure<strong><em> </em></strong>to trauma, surgery, infection or any rapid reduction in the dosage of the inhaled fluticasone propionate component.</p><p>It is not recommended that patients receive higher than approved doses of <em>Seretide</em>.&nbsp; It is important to review therapy regularly and titrate down to the lowest approved dose at which effective control of disease is maintained (<em>see Dosage and Administration</em>).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Asthma</strong></p><p><strong>&nbsp;</strong></p><p><strong>Salmeterol Multi-center Asthma Research Trial (SMART)</strong></p><p>&nbsp;</p><p>The Salmeterol Multi-center Asthma Research Trial (SMART) was a 28-week US study that evaluated the safety of salmeterol compared to placebo added to usual therapy in adult and adolescent subjects. Although there were no significant differences in the primary endpoint of the combined number of respiratory-related deaths and respiratory-related life-threatening experiences, the study showed a significant increase in asthma-related deaths in patients receiving salmeterol (13 deaths out of 13,176 patients treated&nbsp; with salmeterol versus 3 deaths out of 13,179 patients on placebo). The study was not designed to assess the impact of concurrent inhaled corticosteroid use.&nbsp;</p><p>&nbsp;</p><p><strong>Safety and efficacy of salmeterol-FP versus FP alone in asthma</strong></p><p>&nbsp;</p><p>&nbsp;Two multi-centre 26-week studies were conducted to compare the safety and efficacy of salmeterol-FP versus FP alone, one in adult and adolescent subjects (AUSTRI trial), and the other in paediatric subjects 4-11 years of age (VESTRI trial). For both studies, enrolled subjects had moderate to severe persistent asthma with history of asthma-related hospitalisation or asthma exacerbation in the previous year. The primary objective of each study was to determine whether the addition of LABA to ICS therapy (salmeterol-FP) was non-inferior to ICS (FP) alone in terms of the risk of serious asthma related events (asthma-related hospitalisation, endotracheal intubation, and death). A secondary efficacy objective of these studies was to evaluate whether ICS/LABA (salmeterol-FP) was superior to ICS therapy alone (FP) in terms of severe asthma exacerbation (defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or an in-patient hospitalisation or emergency department visit due to asthma that required systemic corticosteroids).&nbsp;</p><p>&nbsp;</p><p>A total of 11,679 and 6,208 subjects were randomized and received treatment in the AUSTRI and VESTRI trials, respectively. For the primary safety endpoint, non-inferiority was achieved for both trials (see Table below).</p><p>&nbsp;</p><p>Serious Asthma-Related Events in the 26-Week AUSTRI and VESTRI Trials</p><table border="1" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>AUSTRI</p></td><td colspan="2" style="vertical-align:top"><p>VESTRI</p></td></tr><tr><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 5,834)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 5,845)</p></td><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 3,107)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 3,101)</p></td></tr><tr><td style="vertical-align:top"><p>Composite endpoint</p><p>(Asthma-related hospitalisation, endotracheal intubation,<s> </s>or death)</p></td><td style="vertical-align:top"><p>34 (0.6%)</p></td><td style="vertical-align:top"><p>33 (0.6%)</p></td><td style="vertical-align:top"><p>27 (0.9%)</p></td><td style="vertical-align:top"><p>21 (0.7%)</p></td></tr><tr><td style="vertical-align:top"><p>Salmeterol-FP/FP Hazard ratio (95% CI)</p></td><td style="vertical-align:top"><p>1.029</p><p>(0.638-1.662)<sup>a</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>1.285</p><p>(0.726-2.272)<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Death</p></td><td style="vertical-align:top"><p>0</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Asthma-related hospitalisation</p></td><td style="vertical-align:top"><p>34</p></td><td style="vertical-align:top"><p>33</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>21</p></td></tr><tr><td style="vertical-align:top"><p>Endotracheal intubation</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>2</p></td><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp; If the resulting upper 95% CI estimate for the relative risk was less than 2.0, then non-inferiority was concluded.</p><p><sup>b</sup>&nbsp;&nbsp; If the resulting upper 95% CI estimate for the relative risk was less than 2.675, then non-inferiority was concluded.</p><p>For the secondary efficacy endpoint, reduction in time to first asthma exacerbation for salmeterol-FP relative to FP was seen in both studies, however only AUSTRI met statistical significance:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:635px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>AUSTRI</p></td><td colspan="2" style="vertical-align:top"><p>VESTRI</p></td></tr><tr><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 5,834)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 5,845)</p></td><td style="vertical-align:bottom"><p>Salmeterol-FP</p><p>(n = 3,107)</p></td><td style="vertical-align:bottom"><p>FP Alone</p><p>(n = 3,101)</p></td></tr><tr><td style="vertical-align:top"><p>Number of subjects with an asthma exacerbation</p></td><td style="vertical-align:top"><p>480 (8%)</p></td><td style="vertical-align:top"><p>597 (10%)</p></td><td style="vertical-align:top"><p>265 (9%)</p></td><td style="vertical-align:top"><p>309 (10%)</p></td></tr><tr><td style="vertical-align:top"><p>Salmeterol-FP/FP Hazard ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.787</p><p>(0.698, 0.888)</p></td><td colspan="2" style="vertical-align:top"><p>0.859</p><p>(0.729, 1.012)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Twelve month study</strong></p><p><strong>&nbsp;</strong></p><p>A large twelve-month study (Gaining Optimal Asthma ControL, GOAL) in 3416 asthma patients compared the efficacy and safety of <em>SERETIDE</em> versus inhaled corticosteroid alone in achieving pre-defined levels of asthma control. Treatment was stepped-up every 12 weeks until <sup>##</sup>&lsquo;Total control&rsquo; was achieved or the highest dose of study drug was reached. Control needed to be sustained for at least 7 out of the last 8 weeks of treatment. The study showed that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 71% of patients treated with <em>SERETIDE</em> achieved <sup>#</sup>&lsquo;Well-controlled&rsquo; asthma compared with 59% of patients treated with inhaled corticosteroid alone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41% of patients treated with <em>SERETIDE</em> achieved <sup>##</sup>&lsquo;Total control&rsquo; of asthma compared with 28% of patients treated with inhaled corticosteroid alone.</p><p>These effects were observed earlier with <em>SERETIDE</em> compared with inhaled corticosteroid alone and at a lower inhaled corticosteroid dose.</p><p>The GOAL study also showed that:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The rate of exacerbations was 29% lower with <em>SERETIDE</em> compared to inhaled corticosteroid treatment alone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Attaining &lsquo;Well controlled&rsquo; and &lsquo;Totally controlled&rsquo; asthma improved Quality of Life (QoL). 61% of patients reported minimal or no impairment on QoL, as measured by an asthma specific quality of life questionnaire, after treatment with <em>SERETIDE</em> compared to 8% at baseline.</p><p><sup>#</sup>Well controlled asthma; less than or equal to 2 days with symptom score greater than 1 (symptom score 1 defined as &lsquo;symptoms for one short period during the day&rsquo;), SABA use on less than or equal to 2 days and less than or equal to 4 occasions/week, greater than or equal to 80% predicted morning peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy.</p><p><sup>##</sup>Total control of asthma; no symptoms, no SABA use, greater than or equal to 80% predicted morning peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy.</p><p>Two further studies have shown improvements in lung function, percentage of symptom free days and reduction in rescue medication use, at 60% lower inhaled corticosteroid dose with <em>SERETIDE</em> compared to treatment with inhaled corticosteroid alone, whilst the control of the underlying airway inflammation, measured by bronchial biopsy and bronchoalveolar lavage, was maintained.</p><p>Additional studies have shown that treatment with <em>SERETIDE</em> significantly improves asthma symptoms, lung function and reduces the use of rescue medication compared to treatment with the individual components alone and placebo.&nbsp; Results from GOAL show that the improvements seen with <em>SERETIDE</em>, in these endpoints, are maintained over at least 12 months.</p><p>&nbsp;</p><p><strong>Mechanism of action:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-family:"Arial",sans-serif;
mso-bidi-font-family:"Times New Roman";color:black;mso-ansi-language:EN-US;
mso-fareast-language:EN-US;layout-grid-mode:line'><span style='mso-element:
field-begin'></span> DOCVARIABLE vault_nd_2382f43b-b969-47f9-89ca-b8925a1e2202
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-family:"Arial",sans-serif;
mso-bidi-font-family:"Times New Roman";color:black;mso-ansi-language:EN-US;
mso-fareast-language:EN-US;layout-grid-mode:line'><span style='mso-element:
field-end'></span></span></b><![endif]--></p><p><em>Seretide</em> contains salmeterol and fluticasone propionate which have differing modes of action.&nbsp; Salmeterol protects against symptoms, fluticasone propionate improves lung function and prevents exacerbations of the condition.&nbsp; <em>Seretide</em> can offer a more convenient regime for patients on concurrent beta-agonist and inhaled corticosteroid therapy.&nbsp; The respective mechanisms of action of both drugs are discussed below:</p><p><strong>Salmeterol:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_ff614d5e-951d-438a-b9ca-36bbe018b051 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Salmeterol is a selective long-acting (12 hour) beta<sub>2</sub>-adrenoceptor agonist with a long side chain which binds to the exo-site of the receptor.</p><p>These pharmacological properties of salmeterol offer more effective protection against histamine-induced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting beta<sub>2</sub>-agonists.</p><p><em>In vitro</em> tests have shown salmeterol is a potent and long-lasting inhibitor of the release, from human lung, of mast cell mediators such as histamine, leukotrienes and prostaglandin D<sub>2</sub>.</p><p>In man salmeterol inhibits the early and late phase response to inhaled allergen; the latter persisting for over 30 hours after a single dose when the bronchodilator effect is no longer evident.&nbsp; Single dosing with salmeterol attenuates bronchial hyper-responsiveness. These properties indicate that salmeterol has additional non-bronchodilator activity but the full clinical significance is not yet clear.&nbsp; This mechanism is different from the anti-inflammatory effect of corticosteroids.</p><p><strong>Fluticasone propionate:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_8a295431-8c43-46ca-a124-eb4fe4e3fe13 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Fluticasone propionate given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, without the adverse effects observed when corticosteroids are administered systemically.</p><p>Daily output of adrenocortical hormones usually remain within the normal range during chronic treatment with inhaled fluticasone propionate, even at the highest recommended doses in children and adults.&nbsp; After transfer from other inhaled steroids, the daily output gradually improves despite past and present intermittent use of oral steroids, thus demonstrating return of normal adrenal function on inhaled fluticasone propionate.&nbsp; The adrenal reserve also remains normal during chronic treatment, as measured by a normal increment on a stimulation test.&nbsp; However, any residual impairment of adrenal reserve from previous treatment may persist for a considerable time and should be borne in mind (<em>see Warnings and Precautions</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence in animal or human subjects that the administration of salmeterol and fluticasone propionate together by the inhaled route affects the pharmacokinetics of either component.&nbsp; For pharmacokinetic purposes therefore each component can be considered separately.</p><p>In a placebo-controlled, crossover drug interaction study in 15 healthy subjects, coadministration of <em>SEREVENT</em> (50 mcg twice daily inhaled) and the CYP3A4 inhibitor ketoconazole (400 mg once daily orally) for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold Cmax and 15-fold AUC). There was no increase in salmeterol accumulation with repeat dosing. Three subjects were withdrawn from <em>SEREVENT</em> and ketoconazole co-administration due to QTc prolongation or palpitations with sinus tachycardia. In the remaining 12 subjects, co-administration of <em>SEREVENT<strong> </strong></em>and ketoconazole did not result in a clinically significant effect on heart rate, blood potassium or QTc duration. (<em>see Warnings and Precautions, and Interactions</em>)</p><p><strong>Salmeterol:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d353af38-10e0-46ef-8603-004e9f2a2def \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Salmeterol acts locally in the lung therefore plasma levels are not an indication of therapeutic effects.&nbsp; In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma due to the low plasma concentrations at therapeutic doses (approximately 200 picograms/mL or less) achieved after inhaled dosing.&nbsp; After regular dosing with salmeterol xinafoate, hydroxynaphthoic acid can be detected in the systemic circulation, reaching steady state concentrations of approximately 100 nanograms/mL.&nbsp; These concentrations are up to 1000 fold lower than steady state levels observed in toxicity studies.&nbsp; No detrimental effects have been seen following long-term regular dosing (more than 12 months) in patients with airway obstruction.</p><p>An <em>in vitro</em> study showed that salmeterol is extensively metabolised to a-hydroxysalmeterol (aliphatic oxidation) by cytochrome P450 3A4 (CYP3A4). A repeat dose study with salmeterol and erythromycin in healthy volunteers showed no clinically significant changes in pharmacodynamic effects at 500 mg three times daily doses of erythromycin. However, a salmeterol-ketoconazole interaction study resulted in a significant increase in plasma salmeterol exposure. (<em>see Warnings and Precautions, and Interactions</em>)</p><p><strong>Fluticasone propionate:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d5e65248-31f5-461c-a845-d61004e7d813 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>The absolute bioavailability of fluticasone propionate for each of the available inhaler devices has been estimated from within and between study comparisons of inhaled and intravenous pharmacokinetic data.&nbsp; In healthy adult subjects the absolute bioavailability has been estimated for fluticasone propionate Accuhaler/Diskus (7.8%), fluticasone propionate Diskhaler (9.0%), fluticasone propionate Evohaler (10.9%), salmeterol-fluticasone propionate Evohaler (5.3%) and salmeterol-fluticasone propionate Accuhaler/Diskus (5.5%) respectively. In patients with asthma a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed. Systemic absorption occurs mainly through the lungs and is initially rapid then prolonged.&nbsp; The remainder of the inhaled dose may be swallowed but contributes minimally to systemic exposure due to the low aqueous solubility and pre-systemic metabolism, resulting in oral availability of less than 1%.&nbsp; There is a linear increase in systemic exposure with increasing inhaled dose.&nbsp; The disposition of fluticasone propionate is characterised by high plasma clearance (1150 mL/min), a large volume of distribution at steady-state (approximately 300L) and a terminal half-life of approximately 8 hours.&nbsp; Plasma protein binding is moderately high (91%).&nbsp; Fluticasone propionate is cleared very rapidly from the systemic circulation, principally by metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4.</p><p>The renal clearance of fluticasone propionate is negligible (&lt;0.2%) and less than 5% as the metabolite.&nbsp; Care should be taken when co-administering known CYP3A4 inhibitors, as there is potential for increased systemic exposure to fluticasone propionate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence in animal or human subjects that the administration of salmeterol and fluticasone propionate together by the inhaled route affects the pharmacokinetics of either component.&nbsp; For pharmacokinetic purposes therefore each component can be considered separately.</p><p>In a placebo-controlled, crossover drug interaction study in 15 healthy subjects, coadministration of <em>SEREVENT</em> (50 mcg twice daily inhaled) and the CYP3A4 inhibitor ketoconazole (400 mg once daily orally) for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold Cmax and 15-fold AUC). There was no increase in salmeterol accumulation with repeat dosing. Three subjects were withdrawn from <em>SEREVENT</em> and ketoconazole co-administration due to QTc prolongation or palpitations with sinus tachycardia. In the remaining 12 subjects, co-administration of <em>SEREVENT<strong> </strong></em>and ketoconazole did not result in a clinically significant effect on heart rate, blood potassium or QTc duration. (<em>see Warnings and Precautions, and Interactions</em>)</p><p><strong>Salmeterol:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d353af38-10e0-46ef-8603-004e9f2a2def \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Salmeterol acts locally in the lung therefore plasma levels are not an indication of therapeutic effects.&nbsp; In addition there are only limited data available on the pharmacokinetics of salmeterol because of the technical difficulty of assaying the drug in plasma due to the low plasma concentrations at therapeutic doses (approximately 200 picograms/mL or less) achieved after inhaled dosing.&nbsp; After regular dosing with salmeterol xinafoate, hydroxynaphthoic acid can be detected in the systemic circulation, reaching steady state concentrations of approximately 100 nanograms/mL.&nbsp; These concentrations are up to 1000 fold lower than steady state levels observed in toxicity studies.&nbsp; No detrimental effects have been seen following long-term regular dosing (more than 12 months) in patients with airway obstruction.</p><p>An <em>in vitro</em> study showed that salmeterol is extensively metabolised to a-hydroxysalmeterol (aliphatic oxidation) by cytochrome P450 3A4 (CYP3A4). A repeat dose study with salmeterol and erythromycin in healthy volunteers showed no clinically significant changes in pharmacodynamic effects at 500 mg three times daily doses of erythromycin. However, a salmeterol-ketoconazole interaction study resulted in a significant increase in plasma salmeterol exposure. (<em>see Warnings and Precautions, and Interactions</em>)</p><p><strong>Fluticasone propionate:-</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_d5e65248-31f5-461c-a845-d61004e7d813 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif;mso-bidi-font-family:
"Times New Roman";color:black;mso-ansi-language:EN-US;mso-fareast-language:
EN-US;layout-grid-mode:line'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>The absolute bioavailability of fluticasone propionate for each of the available inhaler devices has been estimated from within and between study comparisons of inhaled and intravenous pharmacokinetic data.&nbsp; In healthy adult subjects the absolute bioavailability has been estimated for fluticasone propionate Accuhaler/Diskus (7.8%), fluticasone propionate Diskhaler (9.0%), fluticasone propionate Evohaler (10.9%), salmeterol-fluticasone propionate Evohaler (5.3%) and salmeterol-fluticasone propionate Accuhaler/Diskus (5.5%) respectively. In patients with asthma a lesser degree of systemic exposure to inhaled fluticasone propionate has been observed. Systemic absorption occurs mainly through the lungs and is initially rapid then prolonged.&nbsp; The remainder of the inhaled dose may be swallowed but contributes minimally to systemic exposure due to the low aqueous solubility and pre-systemic metabolism, resulting in oral availability of less than 1%.&nbsp; There is a linear increase in systemic exposure with increasing inhaled dose.&nbsp; The disposition of fluticasone propionate is characterised by high plasma clearance (1150 mL/min), a large volume of distribution at steady-state (approximately 300L) and a terminal half-life of approximately 8 hours.&nbsp; Plasma protein binding is moderately high (91%).&nbsp; Fluticasone propionate is cleared very rapidly from the systemic circulation, principally by metabolism to an inactive carboxylic acid metabolite, by the cytochrome P450 enzyme CYP3A4.</p><p>The renal clearance of fluticasone propionate is negligible (&lt;0.2%) and less than 5% as the metabolite.&nbsp; Care should be taken when co-administering known CYP3A4 inhibitors, as there is potential for increased systemic exposure to fluticasone propionate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HFA 134a.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Expiry date is indicated on the outer package
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Replace the mouthpiece cover firmly and snap it into position.</p><p>Store <em>Seretide</em> Evohaler below 30&deg;C.</p><p>Protect from frost and direct sunlight.</p><p>As with most inhaled medications in pressurised canisters, the therapeutic effect of this medication may decrease when the canister is cold.</p><p>Pressurised container. Do not expose to temperatures higher than 50&deg;C. The canister should not be punctured, broken or burnt even when apparently empty.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Seretide Evohaler comprises a suspension of salmeterol and fluticasone propionate in the non-CFC propellant HFA 134a.The suspension is contained in an aluminium alloy can, sealed with a metering valve. The canisters are fitted into plastic actuators incorporating an atomizing orifice and fitted with dustcaps.</p><p>Seretide Evohaler has been formulated in three strengths and one pack size, delivering 120 actuations per inhaler.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Testing your Evohaler:</p><p>Before using for the first time or if your inhaler has not been use[HA1]&nbsp; for a week or more remove the mouthpiece cover by gently squeezing the sides of the cover, shake the inhaler well, and release two puffs into the air to make sure that it works.</p><p>Using your inhaler :-</p><p><!--[if gte vml 1]><v:group id="Group_x0020_34"
 o:spid="_x0000_s1030" style='position:absolute;left:0;text-align:left;
 margin-left:2.3pt;margin-top:3.4pt;width:7in;height:171pt;z-index:251658752;
 mso-position-horizontal-relative:margin' coordorigin="1044,14937" coordsize="10080,3420"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_35" o:spid="_x0000_s1031"
  type="#_x0000_t202" style='position:absolute;left:1044;top:14937;width:3240;
  height:3420;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDiLV7mwAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/NasJA
EL4LfYdlCl6kbhSNbXQTqlDxauoDjNkxCWZnQ3Zr4tt3BcHbfHy/s8kG04gbda62rGA2jUAQF1bX
XCo4/f58fIJwHlljY5kU3MlBlr6NNpho2/ORbrkvRQhhl6CCyvs2kdIVFRl0U9sSB+5iO4M+wK6U
usM+hJtGzqMolgZrDg0VtrSrqLjmf0bB5dBPll/9ee9Pq+Mi3mK9Otu7UuP34XsNwtPgX+Kn+6DD
/Bk8fgkHyPQfAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAAAAAA
AAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAAAAAA
AAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA4i1e5sAAAADbAAAADwAAAAAA
AAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPQCAAAAAA==
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='mso-no-proof:yes'><v:shapetype id="_x0000_t75"
      coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
      filled="f" stroked="f">
      <v:stroke joinstyle="miter"/>
      <v:formulas>
       <v:f eqn="if lineDrawn pixelLineWidth 0"/>
       <v:f eqn="sum @0 1 0"/>
       <v:f eqn="sum 0 0 @1"/>
       <v:f eqn="prod @2 1 2"/>
       <v:f eqn="prod @3 21600 pixelWidth"/>
       <v:f eqn="prod @3 21600 pixelHeight"/>
       <v:f eqn="sum @0 0 1"/>
       <v:f eqn="prod @6 1 2"/>
       <v:f eqn="prod @7 21600 pixelWidth"/>
       <v:f eqn="sum @8 21600 0"/>
       <v:f eqn="prod @7 21600 pixelHeight"/>
       <v:f eqn="sum @10 21600 0"/>
      </v:formulas>
      <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
      <o:lock v:ext="edit" aspectratio="t"/>
     </v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1030" type="#_x0000_t75"
      style='width:119.25pt;height:86.25pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
       o:title=""/>
     </v:shape></span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>1</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Remove the mouthpiece
     cover by gently squeezing the sides of the cover. <o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>2</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Check inside and
     outside of the inhaler including the mouthpiece for the presence of loose
     objects.<o:p></o:p></span></p>
     <p class=MsoNormal><span style='mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_36" o:spid="_x0000_s1032" type="#_x0000_t202"
  style='position:absolute;left:4824;top:14937;width:3060;height:3060;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='mso-no-proof:yes'><v:shape id="Picture_x0020_4" o:spid="_x0000_i1029"
      type="#_x0000_t75" style='width:119.25pt;height:82.5pt;visibility:visible;
      mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
       o:title=""/>
     </v:shape></span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>3</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Shake the inhaler well
     to ensure that any loose objects are removed and that the contents of the
     inhaler are evenly mixed.</span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_37" o:spid="_x0000_s1033" type="#_x0000_t202"
  style='position:absolute;left:8424;top:14937;width:2700;height:2880;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-no-proof:yes'><v:shape
      id="Picture_x0020_6" o:spid="_x0000_i1028" type="#_x0000_t75" style='width:120pt;
      height:87.75pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
       o:title=""/>
     </v:shape></span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>4</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Hold the inhaler
     upright between fingers and thumb with your thumb on the base, below the
     mouthpiece</span><span lang=EN-GB style='font-size:10.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap anchorx="margin"/>
</v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:676.922px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:675.078px">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Group_x0020_34"
 o:spid="_x0000_s1026" style='position:absolute;margin-left:43.2pt;
 margin-top:261.05pt;width:7in;height:171pt;z-index:251659264;
 mso-position-horizontal-relative:margin' coordorigin="1044,14937" coordsize="10080,3420"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_35" o:spid="_x0000_s1027"
  type="#_x0000_t202" style='position:absolute;left:1044;top:14937;width:3240;
  height:3420;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='mso-no-proof:yes'><v:shapetype id="_x0000_t75"
      coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
      filled="f" stroked="f">
      <v:stroke joinstyle="miter"/>
      <v:formulas>
       <v:f eqn="if lineDrawn pixelLineWidth 0"/>
       <v:f eqn="sum @0 1 0"/>
       <v:f eqn="sum 0 0 @1"/>
       <v:f eqn="prod @2 1 2"/>
       <v:f eqn="prod @3 21600 pixelWidth"/>
       <v:f eqn="prod @3 21600 pixelHeight"/>
       <v:f eqn="sum @0 0 1"/>
       <v:f eqn="prod @6 1 2"/>
       <v:f eqn="prod @7 21600 pixelWidth"/>
       <v:f eqn="sum @8 21600 0"/>
       <v:f eqn="prod @7 21600 pixelHeight"/>
       <v:f eqn="sum @10 21600 0"/>
      </v:formulas>
      <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
      <o:lock v:ext="edit" aspectratio="t"/>
     </v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1027" type="#_x0000_t75"
      style='width:119.25pt;height:86.25pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
       o:title=""/>
     </v:shape></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>1</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Remove the mouthpiece
     cover by gently squeezing the sides of the cover. <o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>2</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Check inside and
     outside of the inhaler including the mouthpiece for the presence of loose
     objects.<o:p></o:p></span></p>
     <p class=MsoNormal><span style='mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_36" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:4824;top:14937;width:3060;height:3060;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='mso-no-proof:yes'><v:shape id="Picture_x0020_4" o:spid="_x0000_i1026"
      type="#_x0000_t75" style='width:119.25pt;height:82.5pt;visibility:visible;
      mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
       o:title=""/>
     </v:shape></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>3</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Shake the inhaler well
     to ensure that any loose objects are removed and that the contents of the
     inhaler are evenly mixed.</span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_37" o:spid="_x0000_s1029" type="#_x0000_t202"
  style='position:absolute;left:8424;top:14937;width:2700;height:2880;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDyWv1+wQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/NasJA
EL4X+g7LFLwU3VRsbKObUAuK10QfYMyOSTA7G7KriW/fFYTe5uP7nXU2mlbcqHeNZQUfswgEcWl1
w5WC42E7/QLhPLLG1jIpuJODLH19WWOi7cA53QpfiRDCLkEFtfddIqUrazLoZrYjDtzZ9gZ9gH0l
dY9DCDetnEdRLA02HBpq7Oi3pvJSXI2C8354//weTjt/XOaLeIPN8mTvSk3exp8VCE+j/xc/3Xsd
5i/g8Us4QKZ/AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAPJa/X7BAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-no-proof:yes'><v:shape
      id="Picture_x0020_6" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:120pt;
      height:87.75pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
       o:title=""/>
     </v:shape></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>4</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Hold the inhaler
     upright between fingers and thumb with your thumb on the base, below the
     mouthpiece</span><span lang=EN-GB style='font-size:10.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap anchorx="margin"/>
</v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="676" height="232" alt="" src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image004.gif" /></td></tr></tbody></table><p>&nbsp;</p><p><!--[if gte vml 1]><v:group id="Group_x0020_34"
 o:spid="_x0000_s1026" style='position:absolute;margin-left:45.5pt;
 margin-top:259.05pt;width:7in;height:171pt;z-index:251659264;
 mso-position-horizontal-relative:margin' coordorigin="1044,14937" coordsize="10080,3420"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="Text_x0020_Box_x0020_35" o:spid="_x0000_s1027"
  type="#_x0000_t202" style='position:absolute;left:1044;top:14937;width:3240;
  height:3420;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='mso-no-proof:yes'><v:shapetype id="_x0000_t75"
      coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
      filled="f" stroked="f">
      <v:stroke joinstyle="miter"/>
      <v:formulas>
       <v:f eqn="if lineDrawn pixelLineWidth 0"/>
       <v:f eqn="sum @0 1 0"/>
       <v:f eqn="sum 0 0 @1"/>
       <v:f eqn="prod @2 1 2"/>
       <v:f eqn="prod @3 21600 pixelWidth"/>
       <v:f eqn="prod @3 21600 pixelHeight"/>
       <v:f eqn="sum @0 0 1"/>
       <v:f eqn="prod @6 1 2"/>
       <v:f eqn="prod @7 21600 pixelWidth"/>
       <v:f eqn="sum @8 21600 0"/>
       <v:f eqn="prod @7 21600 pixelHeight"/>
       <v:f eqn="sum @10 21600 0"/>
      </v:formulas>
      <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
      <o:lock v:ext="edit" aspectratio="t"/>
     </v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_i1027" type="#_x0000_t75"
      style='width:119.25pt;height:86.25pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image001.png"
       o:title=""/>
     </v:shape></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>1</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Remove the mouthpiece
     cover by gently squeezing the sides of the cover. <o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>2</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Check inside and
     outside of the inhaler including the mouthpiece for the presence of loose
     objects.<o:p></o:p></span></p>
     <p class=MsoNormal><span style='mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_36" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:4824;top:14937;width:3060;height:3060;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center'><span
     lang=EN-GB style='mso-no-proof:yes'><v:shape id="Picture_x0020_4" o:spid="_x0000_i1026"
      type="#_x0000_t75" style='width:119.25pt;height:82.5pt;visibility:visible;
      mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png"
       o:title=""/>
     </v:shape></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>3</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Shake the inhaler well
     to ensure that any loose objects are removed and that the contents of the
     inhaler are evenly mixed.</span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_37" o:spid="_x0000_s1029" type="#_x0000_t202"
  style='position:absolute;left:8424;top:14937;width:2700;height:2880;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-no-proof:yes'><v:shape
      id="Picture_x0020_6" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:120pt;
      height:87.75pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image003.png"
       o:title=""/>
     </v:shape></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>4</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Hold the inhaler
     upright between fingers and thumb with your thumb on the base, below the
     mouthpiece</span><span lang=EN-GB style='font-size:10.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap anchorx="margin"/>
</v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left" style="width:729px"><tbody><tr><td style="width:53px">&nbsp;</td></tr><tr><td style="width:53px">&nbsp;</td><td style="width:623px">&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp; &nbsp;&nbsp;</p><p><!--[if gte vml 1]><v:group id="Group_x0020_32"
 o:spid="_x0000_s1026" style='position:absolute;left:0;text-align:left;
 margin-left:-3pt;margin-top:3.9pt;width:522pt;height:185.35pt;z-index:251656704'
 coordorigin="1044,3961" coordsize="10440,3707" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Text_x0020_Box_x0020_14" o:spid="_x0000_s1027" type="#_x0000_t202"
  style='position:absolute;left:4464;top:3961;width:3960;height:3635;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBG0KgjwgAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/RisIw
FETfBf8hXGFfZE111WrXKO6C4quuH3DbXNuyzU1poq1/bwTBx2FmzjCrTWcqcaPGlZYVjEcRCOLM
6pJzBee/3ecChPPIGivLpOBODjbrfm+FibYtH+l28rkIEHYJKii8rxMpXVaQQTeyNXHwLrYx6INs
cqkbbAPcVHISRXNpsOSwUGBNvwVl/6erUXA5tMPZsk33/hwfp/MfLOPU3pX6GHTbbxCeOv8Ov9oH
reALnlfCDZDrBwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBG0KgjwgAAANoAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='margin-left:9.0pt'><span lang=EN-GB
     style='mso-no-proof:yes'><v:shape id="Picture_x0020_8" o:spid="_x0000_i1027"
      type="#_x0000_t75" style='width:146.25pt;height:104.25pt;visibility:visible;
      mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image005.png"
       o:title=""/>
     </v:shape></span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal style='margin-top:0in;margin-right:21.75pt;margin-bottom:
     0in;margin-left:9.0pt;margin-bottom:.0001pt;text-align:justify'><b><span
     style='font-size:10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;
     layout-grid-mode:line'>6</span></b><span style='font-size:10.0pt;
     mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:line'>.
     Just after starting to breathe in through your mouth, press <span
     style='color:black'>firmly</span> down on the top of the inhaler to
     release salmeterol and fluticasone propionate, while still breathing in
     steadily and deeply<o:p></o:p></span></p>
     <p class=MsoNormal align=center style='text-align:center'><span
     style='mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_20" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:8604;top:3961;width:2880;height:3635;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-no-proof:yes'><v:shape
      id="Picture_x0020_10" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:129pt;
      height:104.25pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image006.png"
       o:title=""/>
     </v:shape></span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>7</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. While holding your
     breath, take the inhaler from your mouth and take your finger from the top
     of the inhaler.<span style='mso-spacerun:yes'>  </span>Continue holding
     your breath for as long as is comfortable.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_23" o:spid="_x0000_s1029" type="#_x0000_t202"
  style='position:absolute;left:1044;top:3961;width:3240;height:3707;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" stroked="f">
  <v:textbox>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-no-proof:yes'><v:shape
      id="Picture_x0020_12" o:spid="_x0000_i1025" type="#_x0000_t75" style='width:129pt;
      height:104.25pt;visibility:visible;mso-wrap-style:square'>
      <v:imagedata src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
       o:title=""/>
     </v:shape></span><span lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal style='text-align:justify'><b><span style='font-size:
     10.0pt;mso-ansi-language:EN-US;mso-fareast-language:EN-US;layout-grid-mode:
     line'>5</span></b><span style='font-size:10.0pt;mso-ansi-language:EN-US;
     mso-fareast-language:EN-US;layout-grid-mode:line'>. Breathe out as far as
     is comfortable and then place the mouthpiece in your mouth between your
     teeth and close your lips around it, but do not bite it.</span><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--><img width="700" height="251" alt="" src="file:///C:/Users/iaa10356/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" />&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&lrm;8. To take the second puff keep the inhaler upright and wait about half a minute &lrm;before repeating steps 3 to 7.&lrm;</p><p>&lrm;9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Afterwards rinse your mouth with water and spit it out.</p><p>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the mouthpiece cover by firmly pushing and snapping the cap into position.</p><p><strong>&nbsp;</strong></p><p><strong>IMPORTANT :-</strong></p><p>Do not rush stages 5, 6 and 7.&nbsp; It is important that you start to breathe in as slowly as &lrm;possible just before operating your inhaler.&nbsp; Practise in front of a mirror for the first few &lrm;times.&nbsp; If you see &quot;mist&quot; coming from the top of your inhaler or the sides of your mouth &lrm;you should start again from stage 2.&lrm;</p><p>If your doctor has given you different instructions for using your inhaler, please follow &lrm;them carefully. Tell your doctor if you have any difficulties.&lrm;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Children:-</strong><strong>&lrm;</strong></p><p>Young children may need help and an adult may need to operate the inhaler for them. &lrm;Encourage the child to breathe out and operate the inhaler just after the child starts to &lrm;breathe in.&nbsp; Practice the technique together.&nbsp; Older children or people with weak hands &lrm;should hold the inhaler with both hands.&nbsp; Put the two forefingers on top of the inhaler and &lrm;both thumbs on the base below the mouthpiece.&lrm;</p><p><strong>&nbsp;</strong></p><p><strong>Cleaning:-</strong><strong>&lrm;</strong></p><p>Your inhaler should be cleaned at least once a week.&lrm;</p><p>&lrm;1.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Remove the mouth piece cover.&lrm;</p><p>&lrm;2.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not remove the canister from the plastic casing.&lrm;</p><p>&lrm;3.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wipe the inside and outside of the mouthpiece and the plastic casing with a dry &lrm;cloth, tissue or cotton bud.&lrm;</p><p>&lrm;4.&lrm;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Replace the mouthpiece cover.&lrm;</p><p>DO NOT PUT THE METAL CANISTER INTO WATER.&lrm;</p><p>&nbsp;[HA1]Wording change: Should this be changed to &ldquo;USED&rdquo;?</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
Glaxo Wellcome Production*, Evreux , France
Packed by:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Marketing Authorisation Holder
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Version number: GDS37/ IPI20 
Date of issue: 15 December 2020 

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>